Health
Wegovy Reduced Covid Deaths in Obese Patients, Study Shows
- Study underscores drug’s impact on inflammation, infections
- Drugmakers seek to show range of benefits for costly shots
Wegovy at the Novo Nordisk A/S production facilities in Hillerod, Denmark.
Photographer: Carsten Snejbjerg/BloombergThis article is for subscribers only.
Novo Nordisk A/S’s Wegovy reduced deaths and illness from Covid in a large study that took place during the pandemic, more evidence of the blockbuster shot’s benefits beyond weight loss.
The findings, published Friday in the Journal of the American College of Cardiology, provide a deeper analysis of Novo’s largest Wegovy trial, called Select. When the pandemic hit, the research was already enrolling more than 17,600 people with obesity, now known to be a risk factor for severe Covid, and heart disease.